The skin is often called a 'mirror of aging'—it visibly reflects both intrinsic biological decline and external damage from UV radiation, pollution, stress, and poor sleep. This review proposes an 'In and Out' framework: treating skin aging from both outside (topical creams and serums) and inside (dietary supplements and nutraceuticals) simultaneously. The authors argue this dual approach can address multiple hallmarks of aging—oxidative stress, chronic inflammation, and epigenetic changes—more effectively than either approach alone.
The paper synthesizes existing knowledge about various topical and internal interventions. On the outside, they discuss retinoids, peptides, antioxidants, and emerging exosome-based formulations. Internally, they focus on NAD+ precursors (like NMN and NR), collagen peptides, polyphenols (like resveratrol), and microbiome modulators. They also highlight emerging tools like epigenetic aging clocks and AI-guided personalization as ways to tailor treatments to individuals.
However, this is a **narrative review**—the authors surveyed existing literature and synthesized concepts rather than conducting new experiments or analyzing original data. No clinical trials were performed, no participant outcomes were measured, and no new biomarker data were generated. The credibility of claims depends entirely on which prior studies they cited and how they weighted conflicting evidence.
The paper's strength lies in proposing an integrative framework and noting the plausibility of combining modalities. The weakness is significant: very few of the specific combinations described have been tested in rigorous human trials. For example, while retinoids are well-validated for skin aging, and some polyphenols show promise, the synergy of *combining* specific topical and oral interventions remains largely theoretical. The mention of AI-guided personalization and epigenetic clocks is forward-looking but currently more aspirational than implemented.
This matters for longevity research because skin is an accessible biomarker of systemic aging, and if these combinations work, they could serve as a model for targeting other organs. However, readers should recognize this as a conceptual framework paper, not proof that the combinations work. Individual studies cited within it vary widely in quality and sample size—some are robust, others are preliminary.
The paper also conflates different levels of evidence without clearly distinguishing strong vs. weak support for each claim. For instance, UV protection is unequivocally beneficial; NAD+ precursor effects in humans remain debated; exosome formulations are largely unregulated. A reader cannot tell from this review alone which recommendations are evidence-based vs. speculative.
0 Comments
Log in to join the discussion.